Alunbrig Gets FDA Approval for Frontline ALK-Positive Lung Cancer Patients
FDA has approved Alunbrig or Brigatinib for first-line treatment of patients with ALK-positive metastatic non-small cell lung cancer, as detected by
Everything about lung cancer is here.